2013 News Releases

Webcast ImageWebcast
Clearside Biomedical Inc at the Deutsche Bank 42nd Annual Health Care Conference  (Live)
05/03/17 at 4:10 p.m. ET
Clearside Biomedical Inc at the Deutsche Bank 42nd Annual Health Care Conference
Wednesday, May 3, 2017 4:10 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
08/05/13Clearside Biomedical, Inc. Names Glenn Noronha, Ph.D., Executive Vice President, Research and Development
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases, today announced Glenn Noronha, Ph.D., has been named to the position of Executive Vice President, Research and Development. “Glenn has had extensive experience in planning and executing all stages of drug development that targets retinal diseases, including working ... 
Printer Friendly Version
07/22/13Clearside Biomedical, Inc. Announces Appointment of Gerald D. Cagle, Ph.D. to Board of Directors
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases, today announced the appointment of Gerald D. Cagle, Ph.D., to the company’s Board of Directors. Dr. Cagle is the former Senior Vice President and Chief Scientific Officer of Alcon Laboratories, Inc. “We are delighted to have Dr. Cagle join our Board of Directors”“We... 
Printer Friendly Version
05/01/13Clearside Biomedical to Present Research on Proprietary Retinal Therapeutics Platform at 2013 ARVO Meeting
Pre-clinical Models and Human Safety Data Suggest Potential of Microinjection Drug Delivery Through the Suprachoroidal Space Clearside Biomedical Scientific Founder Henry Edelhauser Will Also Speak at Vision Innovation and Venture Forum    ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases, today announced... 
Printer Friendly Version
03/04/13Clearside Biomedical, Inc. Names Stephen H. Lang Vice President, Commercial Operations
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases, today announced the appointment of Stephen H. Lang as Vice President, Commercial Operations. “Steve’s broad knowledge of ophthalmology and experience in building and leading commercial teams in the U.S. along with his global experience are invaluable assets to us” ... 
Printer Friendly Version
02/25/13Santen Pharmaceutical Co., Ltd. and Clearside Biomedical, Inc. Enter into Financing and Research Collaboration Agreements for Posterior Ocular Disease
Clearside Biomedical Receives Additional Investment of $7.9 Million from Current Investors and Santen Pharmaceuticals Ltd.    EMERYVILLE, Calif. & ALPHARETTA, Ga.--(BUSINESS WIRE)--Santen Inc., a wholly owned subsidiary of Santen Pharmaceuticals Co., Ltd. (Osaka, Japan, Ticker Code 4536JP), and Clearside Biomedical, Inc. announced today that Santen Ltd., the parent company of Santen Inc., has made an investment in Clearside Biomedical Inc. and... 
Printer Friendly Version
02/25/13Clearside Biomedical Names Rafael V. Andino Vice President, Product Development
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases, today announced Rafael V. Andino has been named to the position of Vice President, Product Development. “Rafael’s product development and leadership experience and his proven ability to bring new products to market will be an invaluable asset to us, and he will play... 
Printer Friendly Version
01/10/13Clearside Biomedical Announces Plans for Clinical Testing of CLS1001 (Triamcinolone Acetonide) Suprachoroidal Injectable Suspension for the Treatment of Uveitis
ALPHARETTA, Ga.--(BUSINESS WIRE)--Clearside Biomedical, Inc., a privately held ophthalmic company developing and commercializing targeted therapeutics for the treatment of sight threatening diseases, announced today that the standard 30-day review period by the U.S. Food and Drug Administration (FDA) relating to Clearside’s Investigational New Drug (IND) Application for CLS1001 (triamcinolone acetonide) Suprachoroidal Injectable Suspension for the treatment of... 
Printer Friendly Version